Skip to content
OpenCapital
Get started

Dianthus Therapeutics DNTH Share Based Compensation Expense — Research And Development Expense

Other product segments

Personnel And Related Costs
$8.64M+47.7%
Other Costs
$1.49M+25.5%
Discovery Expenses
$1.36M+51.4%

Similar metrics at other companies

Cognex logo
CGNXResearch, Development and Engineering Expenses — Stock-Based Comp
$5.09M+8.5%
Tango Therapeutics logo
TNGXPersonnel-Related Expenses-RD — Research And Development Expense
$12.93M-6.6%
TG Therapeutics logo
TGTXNon Cash Compensation Research And Development Expenses
$4.88M+46.4%
Scholar Rock logo
SRRKRD Expense Srk439 — Research And Development Expense
$1.76M-58.9%
Scholar Rock logo
SRRKEarly Research — Research And Development Expense
$1.21M-16.8%
Apogee Therapeutics, Inc. logo
APGEReportable Segment Aggregation Before Other Operating — Research And Development Personnel Related Excluding Equity Based Compensation
$18.54M+21.2%

Other financials

Income statement

See full
Revenue$396.0K-81.8%
Operating income-$46.5M-40.3%
Net income-$40.8M-38.4%
EPS (diluted)-$0.85-3.7%

Balance sheet

See full
Cash & equivalents$627.7M+6,105%
Total debt$1.4M-2.3%
Total equity$1.2B+266%
Total assets$1.2B+258%

Cash flow

See full
Operating cash flow-$28.9M-4.4%
CapEx$10.0K-58.3%
Free cash flow-$28.9M-4.4%

Valuation

See full
Market cap$4.51B+662%
Enterprise value$3.88B+565%
P/S1,465.1×+962×

Profitability

See full
Operating margin-4,558.4%-9,354pp
Net margin-4,104.8%-7,304pp
FCF margin-3,561.6%-6,956pp

Returns & leverage

See full
Return on equity-28.6%+3.2pp
Debt / equity0×0.0×
Current ratio29.3×+13.3×

Where this comes from

Reported directly by Dianthus Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The official record: Dianthus Therapeutics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Dianthus Therapeutics's share based compensation expense — research and development expense.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Dianthus Therapeutics's share based compensation expense — research and development expense?
Dianthus Therapeutics (DNTH) reported share based compensation expense — research and development expense of $4.85M in Q1 2026.
How has Dianthus Therapeutics's share based compensation expense — research and development expense changed year-over-year?
Dianthus Therapeutics's share based compensation expense — research and development expense increased by 95.9% year-over-year, from $2.48M to $4.85M.
What does share based compensation expense — research and development expense mean?
This metric represents the portion of total share-based compensation expense allocated specifically to research and development activities. It reflects the non-cash cost of equity-based awards granted to scientists, clinical researchers, and personnel directly involved in the development of the company's therapeutic pipeline. Monitoring this expense helps investors understand the true cost of human capital dedicated to innovation and clinical trial execution.